TMO
FY2026 Q2 · Calendar Q3 2026
Thermo Fisher Scientific Inc.
Thermo Fisher delivered its second consecutive guidance raise of 2026, with Q2 revenue accelerating to 10% year-over-year growth ($11.99 billion) and adjusted EPS up 13% to $6.03, beating consensus estimates on both lines. The quarter featured broad-based strength across pharma/biotech, industrial, academic, and diagnostic end markets, plus the first full quarter of Clario ownership. Management raised full-year revenue guidance to $47.4-$48.1 billion and adjusted EPS to $24.93-$25.33, tightening the floor on revenue while lifting the EPS range meaningfully. A planned microbiology divestiture will fund $1 billion in share repurchases. The stock's roughly 10% abnormal move on the report signals investor recognition that organic growth is re-accelerating after a softer Q1 and that acquisitions are delivering synergies. Whether H2 can sustain this pace and how competitive dynamics in…
EPS surprise+5.4%
Market move+8.7%
